Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial.

@article{Wunderink2011RecombinantTF,
  title={Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial.},
  author={Richard G Wunderink and P. -F. Laterre and Bruno François and Dominique Perrotin and Antonio Artigas and Luis Otero Vidal and Suzana S M Lobo and J M Mongil San Juan and Sung Chul Hwang and Thierry L Dugernier and Steven P. Larosa and Xavier Wittebole and Jean-François Dhainaut and Christopher Doig and Meryl H Mendelson and Christian Zwingelstein and Guoqin Su and Steven M. Opal},
  journal={American journal of respiratory and critical care medicine},
  year={2011},
  volume={183 11},
  pages={1561-8}
}
RATIONALE Severe community-acquired pneumonia (sCAP) is a leading cause of death worldwide. Adjunctive therapies for sCAP are needed to further improve outcome. A systemic inhibitor of coagulation, tifacogin (recombinant human tissue factor pathway inhibitor) seemed to provide mortality benefit in the sCAP subgroup of a previous sepsis trial. OBJECTIVES Evaluate the impact of adjunctive tifacogin on mortality in patients with sCAP. METHODS A multicenter, randomized, placebo-controlled… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
38 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

Similar Papers

Loading similar papers…